Objective-Controversies have arisen from recent mouse studies about the essential role of biliary sterol secretion in reverse cholesterol transport (RCT). The objective of this study was to examine the role of biliary cholesterol secretion in modulating macrophage RCT in Niemann-Pick C1-Like 1 (NPC1L1) liver only (L1 LivOnly ) mice, an animal model that is defective in both biliary sterol secretion and intestinal sterol absorption, and determine whether NPC1L1 inhibitor ezetimibe facilitates macrophage RCT by inhibiting hepatic NPC1L1.
R everse cholesterol transport (RCT) is classically defined as the movement of cholesterol from cells in peripheral tissues to circulating high-density lipoproteins (HDLs) for hepatic uptake, biliary secretion, and fecal disposal. 1, 2 This process is believed to explain, at least in part, why increased plasma HDL-cholesterol is atheroprotective. 3 Recently, an intestinal route for mass cholesterol excretion in the feces has been reported, 4, 5 which has promoted studies of the significance of this nonbiliary route in RCT, using genetic and surgical mouse models deficient in biliary cholesterol secretion. 6, 7 One genetic model used in macrophage RCT assays is the transgenic mice specifically overexpressing human NiemannPick C1-Like 1 (NPC1L1) in liver. 6, 8 Unlike mice lacking the ATP-binding cassette (ABC) transporter B4 (ABCB4), which are deficient in biliary secretion of both cholesterol and phospholipids as well as develops liver cholestasis, 9 NPC1L1 liver transgenic mice exhibit reduced biliary cholesterol secretion without showing signs of liver cholestasis. NPC1L1 is almost exclusively expressed in the small intestine of mice, and its knockout in mice blocks intestinal cholesterol absorption. 10 The function of NPC1L1 can be inhibited by ezetimibe, [10] [11] [12] [13] a potent cholesterol absorption inhibitor, developed to lower blood cholesterol. 14 In humans, NPC1L1 is expressed in liver in addition to intestine. 8, 10, 15 We have previously shown that transgenic overexpression of human NPC1L1 in the mouse liver significantly reduces biliary cholesterol secretion without altering hepatic expression of the heterodimeric hepatobiliary cholesterol exporters, ABCG5 and ABCG8, and this reduction in biliary cholesterol secretion can be rescued by ezetimibe treatment. 8 Using in vivo RCT assay protocol of Rader, 16 Temel et al 6 showed that biliary sterol secretion is not required for macrophage RCT in NPC1L1 liver transgenic mice, and in mice with acute biliary diversion, both mouse models were deficient in biliary sterol secretion into the gut lumen. In striking contrast with this finding, Nijstad et al 7 reported almost simultaneously that biliary cholesterol secretion is required for functional RCT in mice using the similar protocol. They also showed that bile duct ligation in mice or genetic inhibition of biliary sterol secretion in ABCB4 knockout mice dramatically reduces macrophage-to-feces RCT. Furthermore, they showed that pharmacological stimulation of macrophage RCT by a liver X receptor agonist depends on efficient biliary sterol secretion in mice. The mechanistic basis for different conclusions in these 2 studies is unclear.
On average, ≈50% of cholesterol in the gut lumen is absorbed in humans and rodents, 17, 18 and the remainder excreted in feces. Inhibiting intestinal cholesterol absorption by ezetimibe has been shown to dramatically increase macrophage RCT in wild-type mice, 19, 20 a model that does not express NPC1L1 in liver. 10 Altered biliary cholesterol secretion was reported to influence intestinal cholesterol absorption rates. 21, 22 Acute biliary diversion or bile duct ligation reduces intestinal cholesterol absorption and profoundly alters intestinal metabolism, including increases in intestinal cholesterol synthesis. 23, 24 To eliminate effects of cholesterol absorption changes on fecal excretion of bile-derived cholesterol, we crossed cholesterol absorption-deficient NPC1L1 knockout (L1-KO) mice 10 to liver-specific NPC1L1 transgenic mice 8 and generated mice expressing no endogenous NPC1L1, but human NPC1L1 in liver only (L1 LivOnly mice). 25 We have previously shown that ezetimibe treatment increases biliary sterol excretion by inhibiting hepatic NPC1L1. 8, 25 This observation raised an interesting question as follows: can ezetimibe facilitate macrophage RCT by inhibiting hepatic NPC1L1? L1
LivOnly mice provided us a unique opportunity to address this question. In the present study, we performed macrophage RCT assays in L1 LivOnly mice using the mouse primary peritoneal macrophages. We found that the macrophage-to-feces RCT was dramatically reduced in L1
LivOnly mice. The reduction in macrophage RCT in these animals was completely restored by ezetimibe treatment.
Materials and Methods
Materials and Methods are available in online-only Supplement.
Results

Hepatic Overexpression of NPC1L1 Inhibits Biliary Cholesterol Secretion and Increases Cholesterol Levels in Plasma and Liver of L1-KO Mice
In a recent study using L1
LivOnly mice, we found that liverspecific overexpression of human NPC1L1 in mice of NPC1L1 knockout background almost abolished biliary cholesterol secretion, as evidenced by results from bile duct cannulation studies, and significantly increased plasma and hepatic cholesterol levels. 25 Consistently, in the present study using mice of the same genotypes, we found that overexpression of human NPC1L1 in the L1-KO liver remarkably reduced biliary cholesterol concentrations and molar ratios ( Figure 1A ), without significantly altering biliary concentrations and molar ratios of phospholipids ( Figure 1B ) and bile acids ( Figure  1C ). The effect of hepatic NPC1L1 on biliary cholesterol was completely reversed by ezetimibe treatment for 2 weeks ( Figure 1A ). Ezetimibe treatment had no effects on biliary concentrations and molar ratios of phospholipids and bile acids ( Figure 1B and 1C) . In contrast to previous studies using the same liver-specific NPC1L1 transgenic mice on the wildtype background, 8 or on NPC1L1 knockout background, but on a 0.2% cholesterol diet (≈10 times higher than that used in the current study), we observed a significant 35.1% reduction in fecal excretion of neutral sterols (a sum of cholesterol and its bacterial metabolites coprostanol and cholestanone) in L1
LivOnly compared with L1-KO mice on the 0.015% cholesterol diet ( Figure 1D ). This observation suggests the importance of the use of low-cholesterol diet in delineating the role of biliary sterol secretion in fecal sterol excretion in rodents. Interestingly, ezetimibe treatment for 2 weeks in L1 LivOnly mice significantly increased fecal neutral sterol excretion by 46.1% Figure 1D ), suggesting a substantial contribution of biliary cholesterol secretion to fecal cholesterol excretion in our animals on the low-cholesterol diet (0.015%).
Hepatic overexpression of human NPC1L1 in L1-KO mice on the low-cholesterol diet increased plasma and hepatic levels of total cholesterol, free cholesterol, and cholesterol ester (Table) . The increase of blood cholesterol was mainly distributed in the large HDL fraction (Figure 2) , consistent with our previous study showing that increased blood cholesterol is in the apolipoprotein E-rich HDL fraction. 8 Ezetimibe treatment for 2 weeks virtually reversed all of these alterations. Figure 3A) . [ 3 H]-tracer contents were also increased in several tissues of L1 LivOnly mice, including liver, small intestine, lung, and spleen ( Figure 3B) Figure 4A ). Ezetimibe treatment had no effects on biliary [ 3 H]-cholesterol output in L1-KO mice (3.11±0.13% of dose/mL; Figure 4A ), consistent with L1-KO mice being ezetimibe-insensitive. 10 The biliary [
Hepatic Overexpression of NPC1L1 in L1-
3 H]-bile acid output was comparable among 4 groups ( Figure 4B ).
The fecal excretion represents the final step of RCT. We measured fecal excretion of [ LivOnly mice compared with 10.09±0.42% of dose/d per 100 g BW in L1-KO mice), which was virtually reversed by ezetimibe treatment for 2 weeks (a significant 3-fold increase to 10.13±1.31% of dose/d per 100 g BW; Figure 4C ). Ezetimibe treatment did not alter fecal [ 3 H]-neutral sterol excretion in L1-KO mice (9.98±0.51% of dose/d per 100 g BW; Figure 4C ). Hepatic overexpression of human NPC1L1 or its inhibition by ezetimibe did not change fecal [ 3 H]-bile acid excretion in L1-KO mice ( Figure 4D ), which was in agreement with our previous finding that the mass bile acid excretion via feces is similar between L1-KO and L1 LivOnly mice. 
Hepatic Overexpression of NPC1L1 Does Not Affect Hepatic and Intestinal Uptake of [ 3 H]Cholesteryl Oleyl Ether-Labeled HDL in L1-KO Mice
The transport of cholesterol from peripheral tissues to HDL particles is the first step of RCT. Alterations in HDL turnover and hepatic/intestinal uptake thus have the potential to influence fecal disposal of cholesterol. To determine whether hepatic overexpression of NPC1L1 affects HDL turnover and tissue uptake, we injected [ 3 H]Cholesteryl Oleyl Ether ([ 3 H]CEt-HDL) into our mice via the tail vein, and then followed the plasma decay of radioactivity. Hepatic and intestinal uptake was assessed 48 hours after the injection. Despite a significant reduction in the fractional catabolic rate, hepatic and intestinal uptake of [ 3 H]CEt-HDL was not reduced in L1 LivOnly mice ( Figure 5 ), suggesting that reduced macrophage-to-feces cholesterol transport in L1 LivOnly mice may not be a result of decreased availability of liver cholesterol for biliary disposal.
Discussion
In LivOnly mice. Our results demonstrate an essential role of biliary sterol secretion in mediating macrophage-to-feces RCT in mice deficient in intestinal cholesterol absorption. Given that human livers express NPC1L1, 8, 10, 15 our findings suggest that ezetimibe may have a previously unappreciated action: promoting macrophage RCT via direct inhibition of hepatic NPC1L1 in humans.
Recent studies on mice genetically or surgically deficient in biliary cholesterol secretion have shown that fecal excretion of mass cholesterol is independent of biliary cholesterol secretion; therefore, the transintestinal cholesterol efflux concept was developed as an alternative explanation for these observations. 4, 5 This concept was subsequently used to challenge the classic view on RCT, and it was hypothesized that macrophage RCT may occur via the intestinal route. 6, 26 Although the study performed by Temel et al 6 using the liver-specific NPC1L1 transgenic mice on the wild-type background, or using bile-diverted mice, seems to support the nonbiliary route hypothesis on RCT, the opposite conclusion was obtained from a study performed by Nijstad et al 7 using ABCB4 knockout mice, scavenger receptor class B type I knockout mice, mice treated with the liver X receptor, and mice that were subjected to bile duct ligation. Our present work is in agreement with the conclusion of Nijstad et al 7 that "biliary cholesterol secretion represents the major pathway relevant for RCT" in mice, but in contrast with the finding by Temel et al. 6 Although the same liver-specific NPC1L1 transgenic mice were used in the present work and in the study of Temel et al, it should be emphasized that there was a fundamental difference between the 2 animal models. The present study used the liver-specific NPC1L1 transgenic mice that are deficient in intestinal cholesterol absorption as a result of NPC1L1 knockout, whereas Temel et al used the liver-specific NPC1L1 transgenic mice that have normal cholesterol absorption attributable to the presence of endogenous NPC1L1 in the intestine. On average, ≈50% of cholesterol in the intestinal lumen is absorbed. 18 This would suggest that ≈50% of bile-derived cholesterol is reabsorbed without loss in the feces when NPC1L1 is present. In the present study, we eliminated this reabsorption factor that has been shown to dramatically inhibit macrophage RCT. 19, 20 Thus, we believe our animal model is a more reliable system compared with the model used by Temel for examining how biliary cholesterol secretion modulates in vivo RCT. The data from our model clearly demonstrate that biliary cholesterol secretion is essential for macrophage RCT, thereby supporting the classic view on RCT. 1, 2 In addition, our data strongly argue against a role of the transintestinal cholesterol efflux pathway in promoting macrophage RCT, at least in our animal model.
We have previously shown that hepatic overexpression of human NPC1L1 inhibits biliary cholesterol secretion and increases plasma cholesterol without altering hepatic expression of many proteins involved in liver cholesterol homeostasis, including several cholesterol transporters (ABCG5, ABCG8, and ABCA1), HDL receptor scavenger receptor class B type I, and low-density lipoprotein receptor. 8 We have also shown that hepatic NPC1L1 inhibits biliary cholesterol secretion in L1 LivOnly mice. 25 Consistently, the present work showed that hepatic overexpression of human NPC1L1 inhibited biliary [ LivOnly mice (Figure 3 ). Ezetimibe was developed to inhibit intestinal cholesterol absorption to lower blood cholesterol.
14 In our previous studies, we found that the drug also inhibits hepatic NPC1L1 function to promote biliary cholesterol secretion. 8, 25 The present work showed that ezetimibe increases macrophageto-feces RCT by inhibiting hepatic NPC1L1. It has been previously reported by others that ezetimibe treatment stimulates macrophage RCT in wild-type mice. 19, 20 In those studies, the effect of ezetimibe on RCT should be considered as a result of inhibition of intestinal cholesterol absorption because mice do not normally express measurable NPC1L1 in the liver. 10 However, the livers of humans and monkeys express NPC1L1. 8, 10, 11, 15 A clinical trial [NCT00701727, Ezetimibe RCT Pilot Study. Weblink: http://clinicaltrials.gov/show/ NCT00701727] was initiated to examine the effect of ezetimibe on RCT in humans. On the basis of the results posted on the Web site of this trial, ezetimibe treatment at 10 mg/d for 7 weeks significantly increased fecal excretion of plasmaderived cholesterol in hypercholesterolemic humans. Our present work suggests that ezetimibe may promote RCT in humans through inhibiting NPC1L1 function in both intestine and liver.
In conclusion, biliary sterol secretion plays a key role in promoting macrophage-to-feces RCT. Ezetimibe promotes macrophage RCT via inhibiting hepatic NPC1L1 function to stimulate biliary cholesterol secretion, at least, in mice. Additionally, the data from our animal model strongly argue against a role of the transintestinal cholesterol efflux pathway in promoting macrophage RCT.
